MedTrace Logo

Antiemetic Prophylaxis With Fosaprepitant and Ondansetron in Patients Undergoing Thoracic Surgery

NCT05881486 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2023-06-06

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the efficacy, safety and feasibility of intravenous Fosaprepitant and Ondansetron for the prevention of postoperative nausea and vomiting in thoracicsurgery patients. Participants will be randomized in a 1:1 ratio to the Fosaprepitant and Ondansetron group.The groups were analyzed and compared for frequency of vomiting in 24 h after surgery. In addition, we will further compare the occurrence of postoperative pulmonary complications, length of hospital stay, nutrition and quality of life after surgery in patients treated with different antiemetic prophylaxis.

Conditions

  • Postoperative Nausea and Vomiting
  • Anesthesia Complication
  • Thoracic Diseases

Interventions

DRUG

Ondansetron 8mg

8 mg Ondansetron+100 ml normal saline

DRUG

Fosaprepitant 150 mg

150 mg fosaprepitant +100 ml normal saline

Sponsors & Collaborators

  • Qilu Hospital of Shandong University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2023-06-30
Completion
2023-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05881486 on ClinicalTrials.gov